| |
| |
|
| Insider
Information: |
Sachdev Amit |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
71,325 |
|
|
Indirect Shares
|
7,447 |
|
|
| Direct
Value |
$26,276,609 |
|
|
|
Indirect Value
|
$3,536,953 |
|
|
| Total
Shares |
78,772 |
|
|
| Total
Value |
$29,813,561 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP Chief Patient & Ex... |
2024-05-15 |
55,325 |
2024-05-15 |
7,447 |
Premium* |
|
|
Celladon Corp |
CLDN |
|
2022-03-11 |
16,000 |
2020-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
193 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-02-03 |
4 |
AS |
$228.89 |
$946,845 |
D/D |
(4,097) |
36,190 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-20 |
4 |
AS |
$420.79 |
$1,790,041 |
D/D |
(4,254) |
63,989 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-10-25 |
4 |
OE |
$91.05 |
$392,517 |
D/D |
4,311 |
37,727 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-10-25 |
4 |
AS |
$195.01 |
$840,688 |
D/D |
(4,311) |
33,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2021-02-11 |
4 |
AS |
$210.43 |
$939,068 |
D/D |
(4,460) |
63,542 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-02-05 |
4 |
OE |
$77.31 |
$367,327 |
D/D |
4,520 |
43,683 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-02-05 |
4 |
AS |
$158.55 |
$736,800 |
D/D |
(4,520) |
39,163 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Public Policy,Gov Affairs |
• – – |
2010-10-26 |
4 |
AS |
$37.50 |
$170,025 |
D/D |
(4,534) |
44,910 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2023-02-13 |
4 |
D |
$298.26 |
$1,388,997 |
D/D |
(4,657) |
72,484 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2010-10-28 |
4 |
AS |
$38.50 |
$182,875 |
D/D |
(4,750) |
40,160 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-11-25 |
4 |
OE |
$109.14 |
$545,700 |
D/D |
5,000 |
38,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-11-25 |
4 |
AS |
$220.00 |
$1,100,000 |
D/D |
(5,000) |
33,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-12-09 |
4 |
AS |
$225.00 |
$1,125,000 |
D/D |
(5,000) |
33,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-12-09 |
4 |
OE |
$109.14 |
$545,700 |
D/D |
5,000 |
38,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-01-08 |
4 |
AS |
$230.00 |
$1,150,000 |
D/D |
(5,000) |
36,190 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-01-08 |
4 |
OE |
$109.14 |
$545,700 |
D/D |
5,000 |
41,190 |
0 |
- |
|
| CLDN |
Celladon Corp |
Director |
– • – |
2020-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
0 |
- |
|
| CLDN |
Celladon Corp |
Director |
– • – |
2021-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Policy, Access & Value |
• – – |
2015-03-23 |
4 |
AS |
$122.78 |
$638,756 |
D/D |
(5,083) |
84,901 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-01-23 |
4 |
AS |
$165.00 |
$960,960 |
D/D |
(5,824) |
39,163 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2018-01-23 |
4 |
OE |
$86.52 |
$503,892 |
D/D |
5,824 |
44,987 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Policy, Access & Value |
• – – |
2015-02-18 |
4 |
AS |
$112.62 |
$670,256 |
D/D |
(5,937) |
89,984 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Policy, Access & Value |
• – – |
2015-10-30 |
4 |
AS |
$123.34 |
$745,433 |
D/D |
(5,938) |
78,963 |
0 |
- |
|
| CLDN |
Celladon Corp |
|
• • – |
2022-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
16,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Global Gov. Strategy |
• – – |
2013-07-11 |
4 |
AS |
$84.00 |
$588,000 |
D/D |
(7,000) |
28,987 |
0 |
- |
|
193 Records found
|
|
Page 4 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
